Search Results - "TOPPMEYER, Deborah"

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer by George, Mridula A., Qureshi, Sadaf, Omene, Coral, Toppmeyer, Deborah L., Ganesan, Shridar

“…Targeted therapies such as Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors have improved the prognosis of metastatic hormone receptor (HR) positive breast…”
Get full text

Clinical efficacy of PARP inhibitors in breast cancer by Pandya, Karan, Scher, Alyssa, Omene, Coral, Ganesan, Shridar, Kumar, Shicha, Ohri, Nisha, Potdevin, Lindsay, Haffty, Bruce, Toppmeyer, Deborah L., George, Mridula A.

“…BRCA1 and BRCA2 are key tumor suppressor genes that are essential for the homologous recombination DNA repair pathway. Loss of function mutations in these…”
Get full text

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial) by Tung, Nadine, Arun, Banu, Hacker, Michele R, Hofstatter, Erin, Toppmeyer, Deborah L, Isakoff, Steven J, Borges, Virginia, Legare, Robert D, Isaacs, Claudine, Wolff, Antonio C, Marcom, Paul Kelly, Mayer, Erica L, Lange, Paulina B, Goss, Andrew J, Jenkins, Colby, Krop, Ian E, Winer, Eric P, Schnitt, Stuart J, Garber, Judy E

“…Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline mutation carriers ( carriers). Limited data exist for estrogen receptor…”
Get full text

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial by Albain, Kathy S, Gray, Robert J, Makower, Della F, Faghih, Amir, Hayes, Daniel F, Geyer, Charles E, Dees, Elizabeth C, Goetz, Matthew P, Olson, John A, Lively, Tracy, Badve, Sunil S, Saphner, Thomas J, Wagner, Lynne I, Whelan, Timothy J, Ellis, Matthew J, Wood, William C, Keane, Maccon M, Gomez, Henry L, Reddy, Pavan S, Goggins, Timothy F, Mayer, Ingrid A, Brufsky, Adam M, Toppmeyer, Deborah L, Kaklamani, Virginia G, Berenberg, Jeffrey L, Abrams, Jeffrey, Sledge, George W, Sparano, Joseph A

“…Abstract Background Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence…”
Get full text

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer by HAFFTY, Bruce G, QIFENG YANG, REISS, Michael, KEARNEY, Thomas, HIGGINS, Susan A, WEIDHAAS, Joanne, HARRIS, Lyndsay, HAIT, Willam, TOPPMEYER, Deborah

“…To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively…”
Get full text

Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer by Chacko, Geena, Kota, Srigowri, Kumar, Shicha, Ohri, Nisha, Omene, Coral, Ganesan, Shridar, Toppmeyer, Deborah L., George, Mridula A.

“…Bisphosphonates such as zoledronic acid are an important part of adjuvant therapy to reduce the risk of recurrence in early-stage breast cancer. Uveitis…”
Get full text

Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer by Toppmeyer, Deborah L., Press, Michael F.

“…Breast cancer is the most common cancer in women, and approximately 71% of carcinomas are hormone receptor‐positive (HR+) and human epidermal growth factor…”
Get full text

Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow by Kinney, Anita Y, Walters, Scott T, Lin, Yong, Lu, Shou-En, Kim, Arreum, Ani, Julianne, Heidt, Emily, Le Compte, Circe J G, O'Malley, Denalee, Stroup, Antoinette, Paddock, Lisa E, Grumet, Sherry, Boyce, Tawny W, Toppmeyer, Deborah L, McDougall, Jean A

“…Cancer genetic risk assessment (CGRA) is recommended for women with ovarian cancer or high-risk breast cancer, yet fewer than 30% receive recommended genetic…”
Get full text

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial by Sparano, Joseph A, Gray, Robert J, Makower, Della F, Albain, Kathy S, Saphner, Thomas J, Badve, Sunil S, Wagner, Lynne I, Kaklamani, Virginia G, Keane, Maccon M, Gomez, Henry L, Reddy, Pavan S, Goggins, Timothy F, Mayer, Ingrid A, Toppmeyer, Deborah L, Brufsky, Adam M, Goetz, Matthew P, Berenberg, Jeffrey L, Mahalcioiu, Catalin, Desbiens, Christine, Hayes, Daniel F, Dees, Elizabeth C, Geyer, Jr, Charles E, Olson, Jr, John A, Wood, William C, Lively, Tracy, Paik, Soonmyung, Ellis, Matthew J, Abrams, Jeffrey, Sledge, Jr, George W

“…A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine…”
Get more information

SARS‐CoV‐2 nosocomial infection: Real‐world results of environmental surface testing from a large tertiary cancer center by Shah, Mansi R., Jan, Imraan, Johns, Jeremy, Singh, Kuldip, Kumar, Pallavi, Belarmino, Norma, Saggiomo, Kara J., Hayes, Carolyn, Washington, Kimyatta, Toppmeyer, Deborah L., Haffty, Bruce G., Libutti, Steven K., Evens, Andrew M.

“…BACKGROUND Despite consensus guidelines, concern about severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission has dissuaded patients with…”
Get full text

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker by Qureshi, Sadaf, Chan, Nancy, George, Mridula, Ganesan, Shridar, Toppmeyer, Deborah, Omene, Coral

“…Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone…”
Get full text

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer by Sparano, Joseph A, Gray, Robert J, Ravdin, Peter M, Makower, Della F, Pritchard, Kathleen I, Albain, Kathy S, Hayes, Daniel F, Geyer, Charles E, Dees, Elizabeth C, Goetz, Matthew P, Olson, John A, Lively, Tracy, Badve, Sunil S, Saphner, Thomas J, Wagner, Lynne I, Whelan, Timothy J, Ellis, Matthew J, Paik, Soonmyung, Wood, William C, Keane, Maccon M, Gomez Moreno, Henry L, Reddy, Pavan S, Goggins, Timothy F, Mayer, Ingrid A, Brufsky, Adam M, Toppmeyer, Deborah L, Kaklamani, Virginia G, Berenberg, Jeffrey L, Abrams, Jeffrey, Sledge, George W

“…TAILORx established the role of the 21-gene predictor of genetic risk in ascertaining treatment for women with hormone-receptor–positive, human epidermal…”
Get full text

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment by Gandarillas, Sophia, Newland, Elizabeth Schoenberg, Toppmeyer, Deborah, Stephenson, Ryan, Denzin, Lisa, Dasgeb, Bahar

“…The success of immunotherapy has made it a lifesaving treatment, but not without side effects. Currently, the risk factors for developing immune-related…”
Get full text

Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma by Bjørklund, Sunniva Stordal, Panda, Anshuman, Kumar, Surendra, Seiler, Michael, Robinson, Doug, Gheeya, Jinesh, Yao, Ming, Alnæs, Grethe I. Grenaker, Toppmeyer, Deborah, Riis, Margit, Naume, Bjørn, Børresen-Dale, Anne-Lise, Kristensen, Vessela N., Ganesan, Shridar, Bhanot, Gyan

“…Cancer cells can have different patterns of exon usage of individual genes when compared to normal tissue, suggesting that alternative splicing may play a role…”
Get full text

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes by Mehta, Madhura S, Dolfi, Sonia C, Bronfenbrener, Roman, Bilal, Erhan, Chen, Chunxia, Moore, Dirk, Lin, Yong, Rahim, Hussein, Aisner, Seena, Kersellius, Romona D, Teh, Jessica, Chen, Suzie, Toppmeyer, Deborah L, Medina, Dan J, Ganesan, Shridar, Vazquez, Alexei, Hirshfield, Kim M

“…Several epidemiological studies have suggested a link between melanoma and breast cancer. Metabotropic glutamate receptor 1 (GRM1), which is involved in many…”
Get full text

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer by Sparano, Joseph A, Gray, Robert J, Makower, Della F, Pritchard, Kathleen I, Albain, Kathy S, Hayes, Daniel F, Geyer, Charles E, Dees, Elizabeth C, Perez, Edith A, Olson, John A, Zujewski, JoAnne, Lively, Tracy, Badve, Sunil S, Saphner, Thomas J, Wagner, Lynne I, Whelan, Timothy J, Ellis, Matthew J, Paik, Soonmyung, Wood, William C, Ravdin, Peter, Keane, Maccon M, Gomez Moreno, Henry L, Reddy, Pavan S, Goggins, Timothy F, Mayer, Ingrid A, Brufsky, Adam M, Toppmeyer, Deborah L, Kaklamani, Virginia G, Atkins, James N, Berenberg, Jeffrey L, Sledge, George W

“…Patients with early-stage estrogen-receptor–positive, node-negative breast cancer whose 21-gene Oncotype DX profile suggested a low risk of recurrence were…”
Get full text

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner by BOND, Gareth L, HIRSHFIELD, Kim M, TOPPMEYER, Deborah, OFFIT, Kenneth, LEVINE, Arnold J, KIRCHHOFF, Tomas, ALEXE, Gabriella, BOND, Elisabeth E, ROBINS, Harlan, BARTEL, Frank, TAUBERT, Helge, WUERL, Peter, HAIT, William

“…The importance of the p53 stress response pathway in the suppression of tumor formation is well documented. In a previous report, a single nucleotide…”
Get full text

Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis by Loi, Sherene, Salgado, Roberto, Schmid, Peter, Cortes, Javier, Cescon, David W, Winer, Eric P, Toppmeyer, Deborah L, Rugo, Hope S, De Laurentiis, Michelino, Nanda, Rita, Iwata, Hiroji, Awada, Ahmad, Tan, Antoinette R, Sun, Yuan, Karantza, Vassiliki, Wang, Anran, Huang, Lingkang, Saadatpour, Assieh, Cristescu, Razvan, Yearley, Jennifer, Lunceford, Jared, Jelinic, Petar, Adams, Sylvia

“…In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy…”
Get more information

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer by Gorshein, Elan, Matsuda, Kant, Riedlinger, Gregory, Sokol, Levi, Rodriguez-Rodriguez, Lorna, Eladoumikdachi, Firas, Grandhi, Miral, Ganesan, Shridar, Toppmeyer, Deborah L., Potdevin, Lindsay, Toomey, Kathleen, Hirshfield, Kim M., Chan, Nancy

“…Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone…”
Get full text

Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance) by Sharma, Manish R., Mehrotra, Shailly, Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford, Winer, Eric P., Lyss, Alan P., Toppmeyer, Deborah L., Moreno‐Aspitia, Alvaro, Lad, Thomas E., Velasco, Mario, Overmoyer, Beth, Rugo, Hope S., Ratain, Mark J., Gobburu, Jogarao V.

“…Chemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed…”
Get full text